Gene immunotherapy for non-small cell lung cancer.
Historically, limited results have been observed with immunity in non-small cell lung cancer (NSCLC). In the last 5 years, however, several immune-stimulating products have demonstrated enhancement of tumor antigen recognition through activation of dendritic cell-involved processes. Moreover, clinical benefit has been demonstrated in subsets of patients, justifying ongoing phase III investigation. Results of key gene immunotherapies being tested in NSCLC are reviewed. Preliminary results in advanced NSCLC suggest evidence of well-tolerated immune activation with suggested evidence of clinical benefit with respect to survival and response.
Nemunaitis
John J
JJ
Mary Crowley Medical Research Center, Dallas, Texas, USA.
D019496:Cancer Vaccines / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines